SynBioBeta Speaker

Susan Klaeger

Genentech

Principal Scientist

Dr. Susan Klaeger is a Principal Scientist and Group Lead of Immunopeptidomics and Surface Proteomics at Genentech, a role she has held since 2022. Her research is focused on applied proteomics, specializing in immunopeptidomics and proteogenomics to discover and validate novel cancer antigens and biomarkers for therapeutic development. She holds a PhD from the Technical University of Munich and the German Cancer Consortium, where she applied chemoproteomics approaches to study selectivity of clinical kinase inhibitors, followed by a postdoctoral fellowship at The Broad Institute of MIT and Harvard, where her research focused on improving detection of MHC presented peptides, generation of large scale datasets for AI/ML approaches and proteogenomic integration to the discovery of MHC presented peptides derived from novel, unannotated open reading frames.

Sessions Featuring

Susan

This Year

Main Stage Panel

•

9:00 AM

-

9:30 AM

AIxBIO

The Dark Proteome: Why Protein Sequencing Is Science's Next Frontier

Billions of proteins remain uncharacterized - invisible to current tools, unknown in function, and untapped in potential. This fireside chat explores why protein sequencing is poised to become the defining technology of the next decade in biology, what "protein dark matter" really means for drug discovery and synthetic biology, and how the field is building the infrastructure to illuminate what genomics left in the shadows. 

Featuring

Leroy Hood

ISB

Co-founder & Prof.

Jennifer Dionne

Pumpkinseed & Stanford

CEO / Professor

Susan Klaeger

Genentech

Principal Scientist

Michael Koeris

DARPA

Director, BTO

Protecting National Security with Biology

Sue Siegel

Align & Illumina

Board Director

Top 100 Most Influential Women in Silicon Valley. Health-tech rainmaker who built GE’s venture engine.

Main Stage Panel

•

9:00 AM

-

9:30 AM

AIxBIO

The Dark Proteome: Why Protein Sequencing Is Science's Next Frontier

Billions of proteins remain uncharacterized - invisible to current tools, unknown in function, and untapped in potential. This fireside chat explores why protein sequencing is poised to become the defining technology of the next decade in biology, what "protein dark matter" really means for drug discovery and synthetic biology, and how the field is building the infrastructure to illuminate what genomics left in the shadows. 

Featuring

Leroy Hood

ISB

Co-founder & Prof.

Jennifer Dionne

Pumpkinseed & Stanford

CEO / Professor

Susan Klaeger

Genentech

Principal Scientist

Michael Koeris

DARPA

Director, BTO

Protecting National Security with Biology

Sue Siegel

Align & Illumina

Board Director

Top 100 Most Influential Women in Silicon Valley. Health-tech rainmaker who built GE’s venture engine.

Previous Speakers Include